Gonorrhea Clinical Trial Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight's "Gonorrhea Pipeline Insight 2025" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Gonorrhea pipeline landscape. It covers the Gonorrhea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gonorrhea therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Gonorrhea pipeline products in this space.

Download DelveInsight's comprehensive Gonorrhea Pipeline Report to explore emerging therapies, key Gonorrhea Companies, and future Gonorrhea treatment landscapes @ Gonorrhea Pipeline Outlook Report- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Gonorrhea Pipeline Report
• On December 11, 2025 - GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application for Blujepa (gepotidacin), expanding its use as an oral treatment option for adult and paediatric patients aged 12 years and older who weigh at least 45 kg and have limited or no alternative therapies for uncomplicated urogenital gonorrhea caused by susceptible Neisseria gonorrhoeae strains. This approval is intended for situations where standard-of-care treatments are contraindicated, or when patients are unable or unwilling to receive first-line therapy. The milestone builds on the FDA's earlier approval of gepotidacin this year for use in female adult and paediatric patients aged 12 years and above (weighing ≥40 kg) with uncomplicated urinary tract infections (uUTI).
• DelveInsight's Gonorrhea pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Gonorrhea treatment.
• The leading Gonorrhea Companies such as Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, VenatoRx Pharmaceuticals and others.
• Promising Gonorrhea Therapies such as Gepotidacin, Ceftriaxone, Azithromycin, GSK2140944, Solithromycin, Tinidazole, EVO100 and others.

Access DelveInsight's in-depth pipeline Analysis for a closer look at promising breakthroughs @ Gonorrhea Clinical Trials and Studies- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Gonorrhea Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Gonorrhea Pipeline Report also highlights the unmet needs with respect to the Gonorrhea.

Gonorrhea Overview
Gonorrhea is a common sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae, which infects the mucous membranes of the reproductive tract, throat, and eyes. It spreads through vaginal, anal and many people may have no symptoms, making it easy to transmit unknowingly. When symptoms do occur, they can include painful urination, increased vaginal, and pelvic or testicular pain. If left untreated, gonorrhea can lead to serious complications such as pelvic inflammatory disease (PID), infertility, ectopic pregnancy, and increased susceptibility to HIV. The infection is typically treated with antibiotics, though rising antimicrobial resistance has made treatment more challenging in recent years.

Gonorrhea Emerging Drugs Profile

• Gepotidacin: GlaxoSmithKline
Gepotidacin (GSK2140944) belongs to class of antibiotics, called triazaacenaphthylene topoisomerase inhibitors. Gepotidacin works by selectively interacting with two key bacterial enzymes, DNA gyrase and topoisomerase IV (type II topoisomerases), responsible for bacterial replication. The novel MOA confers activity against most target pathogens resistant to established antibiotics, including fluoroquinolones. The drug is in Phase III clinical studies for the treatment of uncomplicated urinary tract infection (uUTI)/gonorrhea.

• Zoliflodacin: Entasis Therapeutics
Zoliflodacin (ETX0914) is an orally bioavailable antibacterial agent. It is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. The drug is in Phase III clinical developmental studies for the treatment of Gonorrhoea.

Explore DelveInsight's expert-driven report today! @ Gonorrhea Unmet Needs- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Gonorrhea pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Gonorrhea with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gonorrhea Treatment.
• Gonorrhea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gonorrhea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gonorrhea market.

Gonorrhea Companies
Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, VenatoRx Pharmaceuticals and others.

Gonorrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Gonorrhea Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Gonorrhea Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Download DelveInsight's latest report to gain strategic insights into upcoming Gonorrhea Therapies and key Gonorrhea Developments @ Gonorrhea Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Gonorrhea Pipeline Report
• Coverage- Global
• Gonorrhea Companies- Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, VenatoRx Pharmaceuticals and others.
• Gonorrhea Therapies- Gepotidacin, Ceftriaxone, Azithromycin, GSK2140944, Solithromycin, Tinidazole, EVO100 and others.
• Gonorrhea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gonorrhea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight's exclusive Gonorrhea Pipeline Report-access it now! @ Gonorrhea Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/gonorrhoea-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Gonorrhoea: Overview
4. Pipeline Therapeutics
5. Therapeutics Assessment
6. Gonorrhoea - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Gonorrhoea Collaboration Deals
9. Late Stage Products (Phase III)
10. Gepotidacin: GlaxoSmithKline
11. Mid Stage Products (Phase II)
12. F 598: Alopexx Pharmaceuticals
13. Early Stage Products (Phase I)
14. Preclinical/Discovery Stage Products
15. GneX 12: TherapyX
16. Inactive Products
17. Gonorrhoea Key Companies
18. Gonorrhoea Key Products
19. Gonorrhoea- Unmet Needs
20. Gonorrhoea- Market Drivers and Barriers
21. Gonorrhoea- Future Perspectives and Conclusion
22. Gonorrhoea Analyst Views
23. Gonorrhoea Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.